Table 2.
Characteristics of included studies and patient population
| Study | Study type | Mean age, years | Gender (Male) | Intervention | Control | Outcome |
|---|---|---|---|---|---|---|
| Urena/2014 | Clinical trial | 81 ± 8 | 217 (49.9%) | TAVR in LBBB patients | TAVR in patients with no LBBB | Moderate-to-severe AR; Stroke |
| Dizon/2015 | Clinical trial | 84.5 ± 7.2 | 1324 (52.3%) | TAVR in LBBB patients | TAVR in patients with no LBBB | PPM implantation |
| Fischer/2018 | Clinical trial | 81.1 ± 8 | 805 (52.7%) | TAVR in LBBB patients | TAVR in patients with no LBBB | Moderate-to-severe AR; Stroke; PPM implantation |
| Toviabrodie/2017 | Clinical trial | 82 | 47 (58%) | TAVR in LBBB patients | TAVR in patients with no LBBB | N/A |
| Doshi/2018 | Clinical trial | N/A | 3929 (47.9%) | TAVR in LBBB patients | TAVR in patients with no LBBB | N/A |
| Bacik/2018 | Clinical trial | 77.1 ± 5.7 | 69 (59.5%) | TAVR in LBBB patients | TAVR in patients with no LBBB | N/A |
yrs: years; TAVR: Transcatheter aortic valve replacement; LBBB: Left bundle branch block; AR: Aortic regurgitation; PPM: Permanent pacemaker; N/A: Not applicable.